- AimedBio has received Investigational New Drug (IND) approval for AMB302 from the Korea Ministry of Food and Drug Safety (MFDS).
- Biohaven, which holds the global development and commercialization rights to AMB302, initiated a Phase 1 clinical trial in the United States in March 2025.